Autoinflammatory Syndrome with Pyogenic Bacterial Infection and Amylopectinosis

Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis is a very rare inherited disease in which the immune system is wired incorrectly from birth. Children usually develop long-lasting or repeat fevers and body-wide inflammation (autoinflammation), and at the same time they are unusually prone to serious bacterial (and sometimes viral) infections. In many patients, an abnormal starch-like substance called amylopectin builds up inside muscles and sometimes the heart, which can lead to weakness or heart problems; this buildup is often called amylopectinosis or polyglucosan body disease. The condition is most often caused by harmful changes (variants) in genes that form the LUBAC complex—especially RBCK1 (also known as HOIL-1) and sometimes RNF31 (also known as HOIP). LUBAC normally adds “linear” ubiquitin chains that fine-tune pathways like NF-κB to balance inflammation and host defense; when LUBAC fails, people get both uncontrolled inflammation and poor infection control. PMC+3Orpha.net+3rarediseases.info.nih.gov+3

This condition is a very rare, inherited disease in which the body’s “emergency” immune system (innate immunity) is over-active and inflamed, while parts of the infection-fighting system are too weak. Children usually start with repeated fevers and serious bacterial infections in early life. At the same time, a starchy, glycogen-like material called amylopectin (also called polyglucosan) can build up inside muscles (including the heart), which may cause weak muscles and heart problems. Doctors therefore see three main themes together: (1) ongoing inflammation, (2) unusual vulnerability to infections, and (3) storage of amylopectin in muscle. rarediseases.info.nih.gov+1

LUBAC adds linear ubiquitin chains that stabilize signaling complexes upstream of NF-κB, tuning inflammation and antimicrobial responses. When HOIL-1/RBCK1 or HOIP/RNF31 are deficient, (a) inflammation may run unchecked, and (b) antimicrobial defenses are incomplete, allowing pyogenic infections. Separately—and still being clarified—RBCK1 deficiency is linked to faulty glycogen handling and amylopectin (polyglucosan) build-up in muscle and heart. Experimental models show that dialing down glycogen synthase can reduce amylopectinosis, highlighting a metabolic arm of the disease. PubMed+1

Researchers first described families with biallelic (both-copy) HOIL-1/RBCK1 loss-of-function variants who had early-onset autoinflammation, recurrent invasive pyogenic infections, combined immunodeficiency, and deposits of polyglucosan (amylopectin-like) material in muscle and other tissues. Similar features have since been reported with HOIP/RNF31 deficiency. These discoveries established “LUBAC deficiency” as the core disease mechanism for this syndrome. Rupress+3PMC+3PubMed+3

At the cell level, NF-κB signaling is oddly split: some cells (like fibroblasts) signal too weakly, while circulating immune cells (like monocytes) can be over-reactive to IL-1β. This mixture explains why patients have both autoinflammation and immunodeficiency. Meanwhile, loss of HOIL-1 ligase activity promotes polyglucosan (amylopectin) accumulation in muscle and other organs, linking the immune problem to the muscle/heart problem. PubMed+1

Other names

You may also see this condition described as:

• HOIL-1 deficiency; RBCK1 deficiency; RBCK1-related disease. PMC+1

• HOIP deficiency (when the affected gene is RNF31). PMC+1

• LUBAC deficiency (umbrella term covering HOIL-1/HOIP defects). PMC

• Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis (Orphanet/GARD name). Orpha.net+1

• RBCK1-associated polyglucosan body myopathy-1 (PGBM1), sometimes “with immunodeficiency/autoinflammation.” ScienceDirect

Types

Doctors don’t use rigid “types,” but patients tend to fall into practical groupings based on the gene affected and the main organs involved:

1. RBCK1/HOIL-1–predominant disease – early-onset autoinflammation + recurrent serious infections; variable muscle weakness and cardiomyopathy from amylopectin deposits. PMC+1

2. RNF31/HOIP–predominant disease – overlapping autoinflammation/immunodeficiency; amylopectinosis may be present or mild/variable; some patients have lymph-vessel abnormalities (lymphangiectasia). PMC

3. Muscle-dominant PGBM1 – RBCK1 variants where muscle/heart symptoms lead and immune features are subtle or appear later (“expanding phenotype”). PubMed+1

4. Gut-inflammation–dominant presentations – chronic diarrhea and intestinal inflammation with bacterial susceptibility, linked to HOIL-1 roles in innate lymphoid cells (emerging understanding). PMC

Causes

1. Biallelic loss-of-function variants in RBCK1 (HOIL-1) break LUBAC assembly, the core cause in many families. PMC

2. Loss-of-function variants in RNF31 (HOIP) can produce a similar syndrome. PMC

3. Defective linear (M1-linked) ubiquitination disrupts NF-κB pathway control. PMC

4. Cell-type–specific NF-κB imbalance (weak in fibroblasts, hyper in monocytes) fuels both immunodeficiency and autoinflammation. PubMed

5. Impaired responses to IL-1 family signaling in key cells shift inflammation “set-points.” PubMed

6. Reduced stability of the full LUBAC complex when one subunit (HOIL-1) is missing. PMC

7. Polyglucosan (amylopectin) accumulation in muscle/heart due to loss of HOIL-1 E3 ligase activity on unbranched glycogen-like chains. Embo Press

8. Pathogenic RBCK1 variants outside the N-terminus can still cause disease (broader mutational spectrum). PMC

9. De novo or rare RNF31 variants that reduce HOIP function (rare HOIP deficiency). Rupress

10. Secondary strain from infections—intercurrent bacterial or viral illnesses can trigger inflammatory flares in a system already dysregulated. rarediseases.info.nih.gov

11. Intestinal immune dysregulation (HOIL-1 and innate lymphoid cells) predisposing to chronic enteritis and bacterial overgrowth. PMC

12. Lymphatic involvement (lymphangiectasia) in HOIP deficiency may worsen nutrition and immunity. PMC

13. Cardiac stress from amylopectin deposits contributes to cardiomyopathy and clinical deterioration. PubMed

14. Skeletal-muscle damage from polyglucosan bodies causing weakness and exercise intolerance. ScienceDirect

15. Genetic background and modifier genes likely influence severity and organ focus (suggested by variable phenotypes). ScienceDirect

16. Age-related accumulation of polyglucosan can progress myopathy over time. ScienceDirect

17. Inadequate antibody responses (part of combined immunodeficiency) permit recurrent pyogenic infections. rarediseases.info.nih.gov

18. Defective killing or activation pathways in phagocytes from LUBAC signaling faults. PMC

19. Systemic inflammatory “set-point” shift with elevated acute-phase markers between flares. Orpha.net

20. Misdiagnosis as glycogen storage disease IV (GSD-IV) delays correct care; overlap exists but genetic testing separates them. Wiley Online Library

Common symptoms and signs

1. Recurrent or persistent fevers beginning in infancy or early childhood. Orpha.net+1

2. Serious, invasive pyogenic bacterial infections (e.g., pneumonia, sepsis, deep tissue infections). Orpha.net

3. Recurrent viral infections in some patients due to combined immunodeficiency. rarediseases.info.nih.gov

4. Chronic inflammation symptoms: malaise, poor weight gain, high inflammatory blood tests. Orpha.net

5. Muscle weakness that may slowly progress; sometimes exercise intolerance. ScienceDirect

6. Cardiomyopathy (enlarged or weak heart) related to amylopectin deposits. PubMed

7. Chronic diarrhea and gut inflammation in subsets of patients. PMC

8. Swollen lymph vessels / lymphangiectasia (especially with HOIP deficiency). PMC

9. Rashes or inflammatory skin findings during flares (part of autoinflammation spectrum). Orpha.net

10. Failure to thrive / growth concerns in severe early-onset cases. rarediseases.info.nih.gov

11. Fatigue from chronic inflammation and muscle involvement. ScienceDirect

12. Breathing symptoms if there is recurrent pneumonia or cardiomyopathy. Orpha.net

13. Arthralgia or joint swelling during inflammatory episodes. Orpha.net

14. Elevated infection markers (e.g., high CRP/ESR) between or during flares. Orpha.net

15. Neuromuscular signs (reduced reflexes, proximal weakness) in muscle-dominant phenotypes. ScienceDirect

Diagnostic tests

A) Physical examination (bedside assessment)

1. General exam during fever – temperature charting; look for rash, lymph nodes, mouth ulcers, or organ enlargement to document autoinflammation pattern. Orpha.net

2. Muscle exam – test proximal strength (hips/shoulders), tone, and endurance to screen for polyglucosan myopathy. ScienceDirect

3. Cardiac exam – listen for gallop or murmurs; check heart size and signs of heart failure linked to cardiomyopathy. PubMed

4. Abdominal exam – look for tenderness and signs of chronic enteritis or lymphangiectasia (e.g., edema from protein loss). PMC

5. Growth and nutrition check – chart weight/height and screen for malabsorption or chronic inflammation effects. rarediseases.info.nih.gov

B) “Manual”/functional tests (office-based procedures)

6. Six-minute walk / functional endurance – simple measure of exercise tolerance when muscle involvement is suspected. ScienceDirect

7. Manual muscle testing (MRC scale) – structured grading of muscle strength to track myopathy over time. ScienceDirect

8. Pain/weakness provocation maneuvers – repeated sit-to-stand or stair-climb to unmask proximal weakness. ScienceDirect

9. Infection risk screening – standardized questionnaires (otitis, pneumonia, skin abscesses frequency) to quantify susceptibility. rarediseases.info.nih.gov

10. Stool alpha-1 antitrypsin or clinical checks for protein-losing enteropathy if lymphangiectasia suspected. PMC

C) Laboratory & pathological tests

11. Inflammatory markers (CRP, ESR, serum amyloid A) – often raised and useful for tracking flares. Orpha.net

12. Immunologic work-up – immunoglobulin levels, lymphocyte subsets, vaccine antibodies; many patients show combined immunodeficiency features. rarediseases.info.nih.gov

13. Cytokine/IL-1β pathway assays – research or specialized labs can show the paradox (monocyte hyper-responsiveness vs fibroblast hyporesponsiveness). PubMed

14. Muscle or tissue biopsy – shows polyglucosan bodies (PAS-positive, diastase-resistant amylopectin-like material) confirming amylopectinosis. ScienceDirect

15. Genetic testing – sequencing of RBCK1 (HOIL-1) and RNF31 (HOIP) to confirm LUBAC deficiency; variant interpretation may require expert review. ScienceDirect+1

16. NF-κB pathway studies (specialized) – assess linear ubiquitination/NEMO signaling defects that support diagnosis. PMC

D) Electrodiagnostic tests

17. Electromyography (EMG) and nerve conduction studies – help document myopathic patterns and exclude neuropathy when weakness is present. nmd-journal.com

18. ECG – screens for rhythm problems that can accompany cardiomyopathy; baseline for follow-up. PubMed

E) Imaging tests

19. Echocardiography – evaluates heart size and squeezing function (ejection fraction) to detect cardiomyopathy. PubMed

20. Muscle MRI – maps muscle involvement and can guide biopsy in polyglucosan myopathy phenotypes. ScienceDirect

Non-pharmacological treatments

1. Infection-prevention bundle at home and school — Detailed hygiene (handwashing, wound care), safe food/water, and crowd avoidance during outbreaks reduce exposure to pyogenic bacteria in a child with combined immunodeficiency. Purpose: fewer infections; Mechanism: lowers microbial load reaching mucosa/skin. ScienceDirect

2. Vaccination strategy (household “cocooning” + inactivated vaccines for patient as advised) — Family members up-to-date on vaccines; patient receives inactivated vaccines per immunology advice (live vaccines often avoided in combined immunodeficiency). Purpose: indirect/direct protection; Mechanism: herd protection around a vulnerable host. primaryimmune.org

3. Prompt fever plan — Written plan for same-day evaluation of fevers or focal symptoms; lowers risk of overwhelming sepsis. Mechanism: early detection and antibiotics reduce bacterial proliferation and complications. Frontiers

4. Antimicrobial prophylaxis protocols (non-drug “how” aspect: adherence, timing, cultures) — While using physician-prescribed prophylaxis, families use checklists to ensure doses, track cultures, and escalate promptly. Mechanism: improves efficacy of medical prophylaxis and stewardship. Frontiers

5. Nutrition optimized for infection recovery and heart/muscle health — Adequate protein/energy; sodium moderation if cardiomyopathy; avoidance of raw/unsafe foods. Mechanism: supports immune repair and limits heart strain. MedlinePlus

6. Physiotherapy (graded activity for deconditioning) — When muscle involvement exists, supervised strength/balance work preserves function and prevents falls without over-fatigue. Mechanism: improves neuromuscular efficiency around metabolically vulnerable fibers. PMC

7. Cardiac rehabilitation elements (for cardiomyopathy) — Gentle aerobic conditioning and education tailored by cardiology improve exercise tolerance and quality of life. Mechanism: peripheral conditioning reduces cardiac workload. nmd-journal.com

8. Respiratory physiotherapy if weakness or heart failure — Airway clearance, incentive tools, vaccination against pneumococcus/flu for household. Mechanism: lowers pneumonia risk and hospitalizations. Frontiers

9. Central-line care education (if IVIG/antibiotics via device) — Strict sterile technique lowers catheter-related infections. Mechanism: reduces Staph/Strep line sepsis in immune-fragile patients. Frontiers

10. Dental/oral hygiene intensification — Reduces odontogenic seeding of pyogenic organisms. Mechanism: lowers bacteremia episodes. ScienceDirect

11. Skin barrier care — Moisturizers, prompt care of cuts to prevent cellulitis/abscesses. Mechanism: keeps bacterial counts low at portals of entry. ScienceDirect

12. Individualized school/childcare plans — Absence during outbreaks; ventilation and masking policies when advised by clinicians. Mechanism: reduces exposure events. Frontiers

13. Genetic counseling for family planning — Explains autosomal-recessive inheritance, carrier testing, and prenatal options. Mechanism: informed risk management. Orpha.net

14. Psychological support — Long-term rare disease care benefits from counseling for parents/caregivers to reduce stress that can impair adherence. Mechanism: improves care continuity and outcomes. JRheum

15. Physician-led exercise pacing — Avoid over-exertion that may worsen fatigue in myopathy; prioritize low-impact, interval walks. Mechanism: energy conservation with gradual conditioning. nmd-journal.com

16. Heart-failure self-management education — Daily weights, sodium tracking, symptom diary for edema/breathlessness; triggers for urgent review. Mechanism: early decompensation detection. nmd-journal.com

17. Bone health support — Weight-bearing activity and vitamin D/calcium intake as advised, especially if steroids are used. Mechanism: counters steroid-related bone loss. JRheum

18. Infection-control training for caregivers (PPE, cleaning) — Home protocols for disinfecting high-touch surfaces and safe care during sibling illness. Mechanism: lowers secondary household transmission. ScienceDirect

19. Care coordination in a combined immunology–rheumatology–cardiology clinic — Multidisciplinary review catches complications earlier. Mechanism: integrated decisions across inflammation, infection, and heart/muscle care. ScienceDirect

20. Clinical-trial engagement when available — For example, metabolic approaches inspired by glycogen synthase down-regulation (animal data) may evolve; families can monitor research registries. Mechanism: access to emerging therapies for amylopectinosis. PMC

---

Drug treatments

Important: Dosing is individualized by specialists; the ranges below are typical pediatric/young-adult starting points or common clinical use windows from related conditions and general practice. Always follow the treating team’s exact plan.

1. Intravenous immunoglobulin (IVIG) — Class: pooled antibodies. Use: monthly (e.g., 0.4–1 g/kg every 3–4 weeks). Purpose: reduce severe infections in combined immunodeficiency. Mechanism: supplies broad antibodies to opsonize bacteria and modulate inflammation. Key side effects: headache, aseptic meningitis, thrombosis risk; infusion reactions. Evidence and common role across PIDs. Frontiers

2. Broad-spectrum empiric antibiotics for febrile illness — Class: beta-lactams ± aminoglycosides/others per local guidelines. Use: immediately at presentation for suspected sepsis. Purpose: treat pyogenic infections early. Mechanism: bactericidal activity against common invasive pathogens. Side effects: allergy, C. difficile, nephro/ototoxicity (aminoglycosides). ScienceDirect

3. Antibiotic prophylaxis (e.g., cotrimoxazole) — Class: antimicrobial prophylaxis. Use: daily or intermittent per immunologist. Purpose: prevent recurrent bacterial infections. Mechanism: suppresses colonizing bacteria that seed invasive disease. Side effects: rash, cytopenias, hyperkalemia (rare). Frontiers

4. Antifungal/antiviral prophylaxis as indicated — Class: azoles; acyclovir/valacyclovir, etc. Use: during high-risk periods. Purpose: reduce opportunistic infections in combined immunodeficiency. Mechanism: inhibits fungal sterol synthesis or viral DNA polymerase. Side effects: liver enzyme elevations, drug interactions (azoles). Frontiers

5. Systemic corticosteroids (e.g., prednisolone) — Class: glucocorticoid. Use: short courses for flares; dose varies (e.g., 0.5–1 mg/kg/day then taper). Purpose: calm autoinflammatory flares. Mechanism: broad NF-κB and cytokine suppression. Side effects: hyperglycemia, infection risk, hypertension, growth effects. JRheum

6. Anakinra — Class: IL-1 receptor antagonist. Use: daily subcutaneous dosing (e.g., 1–2 mg/kg/day; ranges wider in refractory SAIDs). Purpose: target IL-1–driven autoinflammation (rationale from LUBAC-pathway links to IL-1). Mechanism: blocks IL-1R to reduce fever/inflammation. Side effects: injection site pain, neutropenia, infection risk. PMC+1

7. Canakinumab — Class: monoclonal antibody to IL-1β. Use: every 4–8 weeks (weight-based). Purpose/mechanism: targeted IL-1β blockade when daily anakinra is impractical. Side effects: infection risk, injection reactions. (Evidence extrapolated from SAIDs; mechanistic rationale in LUBAC deficiency.) JRheum

8. Anti-TNF therapy (e.g., infliximab/adalimumab) — Class: TNF inhibitors. Use: standard dosing as in pediatric rheumatology. Purpose: reduce refractory inflammation; reported improvement in one HOIL-1–deficient patient. Mechanism: blunts TNF-driven cytokine cascade that can feed IL-1 pathways. Side effects: serious infection risk, TB reactivation, demyelination (rare). PMC

9. Tocilizumab — Class: IL-6 receptor blocker. Use: IV or SC per weight. Purpose: option when IL-1/TNF blockade is insufficient and IL-6 signature is high. Mechanism: reduces IL-6–mediated fever/CRP response. Side effects: neutropenia, elevated LFTs, infection risk. (General SAID rationale.) JRheum

10. Colchicine — Class: microtubule inhibitor used in autoinflammatory disorders. Use: daily low dose. Purpose: flare prevention in some innate immune disorders; may be tried in milder inflammatory components. Mechanism: dampens inflammasome activation in neutrophils. Side effects: GI upset, cytopenias (rare). JRheum

11. NSAIDs (e.g., naproxen/ibuprofen) — Class: COX inhibitors. Use: PRN or short courses. Purpose: symptom control for fever/pain during inflammatory flares. Mechanism: blocks prostaglandins to reduce pain/fever. Side effects: gastritis, renal strain. JRheum

12. Aspirin (careful specialist use) — Class: antiplatelet/NSAID. Use: specific indications (e.g., pericarditis). Purpose: reduce inflammation/platelet activation if cardiology advises. Mechanism: COX-1/2 inhibition; antiplatelet effect. Side effects: bleeding, Reye risk in children (avoid unless directed). JRheum

13. Heart-failure medicines (ACE inhibitors, beta-blockers, diuretics) — Class: cardiology standard of care. Use: guideline-directed therapy for cardiomyopathy. Purpose: improve heart function/symptoms in amylopectin cardiomyopathy. Mechanism: neurohormonal blockade, preload/afterload reduction. Side effects: hypotension, electrolyte shifts. nmd-journal.com

14. Mineralocorticoid receptor antagonists (e.g., spironolactone) — Class: HF therapy. Purpose/mechanism: limits adverse remodeling and fluid retention. Side effects: hyperkalemia, gynecomastia. nmd-journal.com

15. Anticoagulation/antiplatelet as indicated in cardiomyopathy — Class: varies. Purpose: prevent thromboembolism in low-EF or device patients when indicated. Mechanism: reduces clot formation. Side effects: bleeding risk. nmd-journal.com

16. Granulocyte colony-stimulating factor (G-CSF) — Class: hematopoietic growth factor. Use: if neutropenia episodes occur. Purpose: boost neutrophils to lower infection risk. Mechanism: stimulates marrow granulopoiesis. Side effects: bone pain, rare splenic issues. Frontiers

17. Pneumocystis prophylaxis (trimethoprim–sulfamethoxazole) — already noted under prophylaxis but listed here for completeness; see #3. Purpose/mechanism: prevents PCP and some bacterial infections. Frontiers

18. IV iron or erythropoiesis support if chronic inflammation causes anemia — Class: supportive hematology. Purpose: address anemia of inflammation to improve energy. Mechanism: replenishes iron, supports RBC production. Side effects: infusion reactions (IV iron). JRheum

19. HSCT conditioning/immune reconstitution regimen (specialist) — Class: cellular therapy protocol (not a single drug). Use: case-selected severe immune phenotype. Purpose: rebuild immune system to correct immunodeficiency/autoinflammation (effect on extra-hematopoietic muscle storage may be limited). Risks: graft-versus-host disease, infections. Frontiers+1

20. Short-term stress-dose steroids during severe infections in chronic steroid users — Class: glucocorticoid coverage. Purpose: prevent adrenal crisis and control inflammation. Risks: hyperglycemia, infection risk. JRheum

---

Dietary molecular supplements

Note: No supplement is proven to cure this syndrome. These are supportive, only if your clinician agrees, often used in PID/heart-muscle care.

1. Vitamin D (e.g., 600–1,000 IU/day or per level) — Supports antimicrobial peptides and immune regulation; deficiency is common in chronic illness. Mechanism: enhances innate immunity and moderates inflammation. JRheum

2. Omega-3 fatty acids (EPA/DHA) (e.g., 1–2 g/day combined) — Anti-inflammatory lipid mediators may modestly reduce systemic inflammation; also beneficial in heart health. Mechanism: resolvin/protectin pathways. JRheum

3. Zinc (e.g., 5–20 mg elemental/day, age-adjusted) — Essential for neutrophil and NK cell function; correct deficiency only. Mechanism: cofactor for immune enzymes. JRheum

4. Vitamin C (e.g., 100–500 mg/day) — Antioxidant support during frequent infections; helps leukocyte function. Mechanism: scavenges ROS, supports neutrophil function. JRheum

5. Coenzyme Q10 (e.g., 100–200 mg/day) — Supportive in cardiomyopathy for energy metabolism. Mechanism: mitochondrial electron transport cofactor. nmd-journal.com

6. Selenium (e.g., 25–50 µg/day if low) — Antioxidant selenoproteins support immune balance and myocardium; correct deficiency only. Mechanism: GPx activity. JRheum

7. Carnitine (e.g., 500–1,000 mg/day) — Sometimes used in muscle/heart energy disorders; discuss with cardiology. Mechanism: fatty-acid transport into mitochondria. nmd-journal.com

8. B-complex (esp. B1, B6, B12) — Supports energy and hematopoiesis; avoid mega-doses. Mechanism: coenzymes in energy and RBC production. JRheum

9. Magnesium (dietary or supplement if low) — Useful in arrhythmia-prone cardiomyopathy; correct deficiency only. Mechanism: stabilizes cardiac conduction. nmd-journal.com

10. Protein adequacy (whey/medical nutrition) — Not a pill, but ensuring enough protein helps muscle maintenance and recovery from infection. Mechanism: supports repair and immune proteins. MedlinePlus

Immunity-booster / regenerative / stem-cell–oriented” therapies

1. Hematopoietic stem cell transplantation (HSCT) — Replaces the faulty immune system with donor stem cells in selected severe phenotypes. It may correct the immunodeficiency/autoinflammation, but muscle/heart amylopectin (an extra-hematopoietic problem) may persist. Decisions are individualized at tertiary centers. Frontiers+1

2. Gene therapy (conceptual for LUBAC defects) — Approved for some PIDs (e.g., ADA-SCID), but not yet for RBCK1/HOIP deficiency; it illustrates a future direction for correcting the root immune defect. Nature

3. Targeted antisense to glycogen synthase (preclinical) — In RBCK1-deficient mice, down-regulating glycogen synthase reduced amylopectin build-up and improved muscle biology, suggesting a metabolic path to treat amylopectinosis in the future. PMC

4. Cardiac devices (ICD/CRT) as “regenerative supports” — Not regeneration per se, but device therapy can stabilize arrhythmias and support remodeling in cardiomyopathy while awaiting recovery/transplant. nmd-journal.com

5. Heart transplantation (advanced cases) — For end-stage cardiomyopathy due to amylopectin storage, heart transplant has been reported and can restore cardiac function when medical therapy fails. JSciMed Central

6. Exercise-based cardiac/neuromuscular rehabilitation — Facilitates functional “re-conditioning” of muscle systems impaired by inflammation and storage, improving daily function alongside medical care. nmd-journal.com

---

Surgeries

1. Heart transplantation — For end-stage cardiomyopathy with poor ejection fraction despite optimal therapy; replaces the diseased heart to restore function. JSciMed Central

2. Implantable cardioverter-defibrillator (± cardiac resynchronization) — To prevent sudden death and improve coordination of a failing heart when arrhythmia risk is high. nmd-journal.com

3. Gastrostomy tube placement — If poor growth or chronic illness limits oral intake, a feeding tube ensures safe nutrition and medication delivery. Frontiers

4. Central venous access device (port) — For frequent IVIG or IV antibiotics; provides reliable access and improves care logistics. Frontiers

5. Muscle biopsy (diagnostic procedure) — Confirms polyglucosan/amylopectin storage and helps guide long-term management. nmd-journal.com

Prevention

1. Keep a written fever plan and act early. 2) Maintain strict hygiene and wound care. 3) Ensure household vaccination is up to date; use inactivated vaccines for the patient as advised. 4) Avoid sick contacts and crowded settings during outbreaks. 5) Practice safe food/water habits. 6) Follow antibiotic/antiviral prophylaxis precisely if prescribed. 7) Protect skin barrier (eczema care, moisturizers). 8) Coordinate regular immunology and cardiology follow-ups. 9) Use dental hygiene to cut bacterial load. 10) Plan travel with access to medical care and a letter explaining the condition. primaryimmune.org+2ScienceDirect+2

---

When to see a doctor

Seek urgent care same day for fever ≥38.0°C, shaking chills, deep skin infections, new cough and breathing trouble, severe sore throat, unusual lethargy, vomiting with dehydration, or any new chest pain, fainting, palpitations, or fast swelling (heart red flags). Ongoing poor weight gain, increasing fatigue, or new weakness should prompt a clinic visit within a few days. Carry your emergency plan and antibiotic allergy list. Frontiers

---

What to eat and what to avoid

Eat: balanced meals with enough protein, fruits/vegetables, whole foods, and adequate calories to support growth and recovery; moderate sodium if cardiology advises for heart failure. Avoid/limit: raw or undercooked eggs/meat/fish; unpasteurized dairy; buffet foods at unsafe temperatures; excess added sugars and ultra-processed foods; and high-salt snacks if heart issues are present. There is no proven disease-specific diet to clear amylopectin in this syndrome; nutrition supports overall strength while medical care targets inflammation and infection. MedlinePlus

---

Frequently asked questions

1. Is this the same as APBD (adult polyglucosan body disease)?
   No. APBD is usually due to GBE1 defects and presents in adults; here the hallmark is early autoinflammation + immunodeficiency with RBCK1/HOIL-1 (or rarely HOIP) defects and amylopectinosis. National Organization for Rare Disorders+1

2. Why do inflammation and infections happen together?
   Faulty LUBAC signaling both over-activates inflammatory pathways and weakens antimicrobial defenses, so patients can be inflamed and infection-prone at the same time. PubMed

3. What exactly is “amylopectinosis”?
   It’s the abnormal accumulation of polyglucosan/amylopectin—a poorly branched glycogen-like substance—in tissues like muscle and heart. nmd-journal.com

4. How is it confirmed?
   By genetic testing and, when needed, biopsy showing polyglucosan bodies, plus immune testing that fits the picture. PubMed

5. Can anti-TNF or IL-1 blockers help?
   Yes, they can be considered. An anti-TNF drug improved inflammation in one reported HOIL-1 patient; IL-1 blockade is biologically plausible and used in related autoinflammatory diseases. Decisions are case-by-case. PMC+1

6. Will IVIG stop all infections?
   It reduces severe infections, but breakthrough infections can happen and still need rapid treatment. Frontiers

7. Is HSCT a cure?
   HSCT can rebuild the immune system in selected severe cases, but may not reverse muscle/heart amylopectin because that problem is outside the blood system. Frontiers+1

8. Are there metabolic treatments for amylopectin build-up?
   Not clinically yet, but animal research shows glycogen-synthase down-regulation can reduce amylopectinosis, offering future directions. PMC

9. Can the heart recover?
   Some stabilize with standard heart-failure care; advanced cases may require devices or transplantation. nmd-journal.com+1

10. Is there a special diet that fixes this?
    No proven “amylopectin-clearing” diet; follow general immunodeficiency and heart-healthy nutrition. MedlinePlus

11. Are live vaccines safe?
    Often avoided in combined immunodeficiency; the immunology team individualizes the plan. Household members should be fully vaccinated. primaryimmune.org

12. What is the outlook?
    Varies by severity. Some patients have severe early disease; others have milder, later-evolving muscle/heart involvement. Early, coordinated care improves outcomes. PubMed

13. Is genetic counseling useful for the family?
    Yes—this is autosomal-recessive; carrier testing helps future planning. Orpha.net

14. Why do some patients mainly have muscle/heart disease?
    RBCK1 disease spans a spectrum—from dominant polyglucosan myopathy/cardiomyopathy to combined immune dysregulation—likely reflecting variant location and modifier factors. PMC

15. Where can clinicians read more?
    Key sources include Orphanet/GARD overviews and original reports describing HOIL-1/HOIP (LUBAC) deficiency. Rupress+3Orpha.net+3rarediseases.info.nih.gov+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 30, 2025.

PDF Documents For This Disease Condition References